News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure has published its financial report for 2023 – the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025
29 March 2024
First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis
22 March 2024
Molecure has submitted a new application for approval to conduct a Phase II clinical trial for clinical candidate OATD-01 in the countries of the European Union and Norway
9 February 2024
Molecure invites to the R&D Day – an online scientific and educational meeting on February 6, 2024
29 January 2024
Molecure’s success in development of the mRNA discovery platform
12 December 2023